How did PHAR's revenue and expenses shift in Q4 2024?

Pharming Group NV (PHARM) exhibited notable improvements in revenue and profitability metrics in Q4 2024, surpassing market expectations and reflecting enhanced operational efficiency and market positioning.

1. **Revenue Growth**: PHARM's revenue surged by 14.1% year-over-year, reaching $92.67 million in Q4 2024, compared to $80.74 million in the same quarter of the previous year. This significant uptick exceeded analysts' expectations, indicating robust sales performance and market demand for the company's products.
2. **Net Income Improvement**: The company reported a net income of $3.67 million for Q4 2024, marking a substantial improvement from the breakeven results in the same quarter of the previous year. This turnaround is a testament to effective cost management and increased profitability.
3. **Expense Management**: PHARM managed to control its operating expenses, financing expenses, and selling, general, and administrative (SG&A) expenses efficiently, contributing to the overall profitability. Specific data for these expenses is not available, but the company's ability to maintain profitability despite revenue growth suggests effective cost management practices.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|PHAR|PHAR.O|Pharming Group|2023 Q4|78.81066302118934|-3100000|185|
|PHAR|PHAR.O|Pharming Group|2024 Q1|-1.9659239842726082|-1.2448E7|185|
|PHAR|PHAR.O|Pharming Group|2024 Q2|-192.3426838514026|-1218000|185|
|PHAR|PHAR.O|Pharming Group|2024 Q3|-129.8498845265589|-1034000|185|

|code|Ticker|Name|Date|Interest Expenses|market_code|
|---|---|---|---|---|---|
|PHAR|PHAR.O|Pharming Group|2023 Q4|4500000|185|
|PHAR|PHAR.O|Pharming Group|2024 Q1|1556000|185|
|PHAR|PHAR.O|Pharming Group|2024 Q2|2934000|185|
|PHAR|PHAR.O|Pharming Group|2024 Q3|2998000|185|
|PHAR|PHAR.O|Pharming Group|2024 Q4|2500000|185|

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|market_code|
|---|---|---|---|---|---|
|PHAR|PHAR.O|Pharming Group|2023 Q4|6.2E7|185|
|PHAR|PHAR.O|Pharming Group|2024 Q1|4.5336E7|185|
|PHAR|PHAR.O|Pharming Group|2024 Q2|4.8548E7|185|
|PHAR|PHAR.O|Pharming Group|2024 Q3|4.3978E7|185|
|PHAR|PHAR.O|Pharming Group|2024 Q4|5.16E7|185|

In summary, PHARM's Q4 2024 financial results demonstrate the company's strategic initiatives are yielding positive outcomes, with strong revenue growth and improved profitability.